The research and development journey for the few drugs that make it to market will have taken at least 12 years and cost around £2bn. The process suffers from a 90% failure rate. This is often due to poor target validation, a critical step that assesses whether the engagement of a specific cellular target with a drug will have the desired therapeutic outcome. This step accounts for up to a staggering 50% of the failure rate.

At GenProtex we are developing a novel technology to address target validation to ensure future drug discovery programmes are carried for the right targets.